
SUPEROXIDE DISMUTASE 1 AND 2 GENE POLYMORPHISM
IN TURKISH VITILIGO PATIENTS Tuna A1, Ozturk G1, Gerceker TB1, Karaca E2,*, Onay H2, Guvenc SM2, Cogulu O2 *Corresponding Author: Emin Karaca, M.D., Associacte Professor, Department of Dermatology and Venerology, Faculty
of Medicine, Ege University, Kazım Dirik mah, Izmir, Turkey. Tel: +90-232-3903961-+90-532-2579285. Fax: +90-232-
3903971. E-mail: karacaemin@gmail.com page: 67
|
INTRODUCTION
Vitiligo, characterized by milky-white patches on the
skin, is an acquired disease of unknown etiology. Histologically
speaking, it is caused by a loss of melanocytes
[1]. Several theories have been proposed to explain the
pathogenesis; these include the autoimmune, the neural
and the theory of self-destruction. Most current studies
have focused on the genetic etiology, with genes related
to the autoimmunity, melanin, and the biological reply
process to the oxidative stress, being the most thoroughly
investigated [2-6].
With regard to the pathogenic role of oxidative stress
in vitiligo, the previous studies were directed toward
changes in antioxidant enzyme activity in the blood and
tissue. Although some conflicting results were attained, all
studies did point to an impact of oxidative stress on vitiligo
[7-12]. Superoxide dismutase (SOD), one of the primary
antioxidant enzymes, was previously studied in relation
to vitiligo and to date, three isoforms of SOD have been
identified in humans. They are coded by three different
genes: copper-zinc SOD (CuZn-SOD), manganese SOD
(Mn-SOD), and extracellular SOD. The diversity in their
form stems from amino acid alignment, active metal zone
and their intra cell location. Copper-zinc SOD, defined as SOD1, is a cytosolic enzyme, Mn-SOD, namely SOD2,
exists in the mitochondria; while the expression of the
SOD3 enzyme, is limited to only plasma, lymphoid tissue
or cerebrospinal liquids [13,14].
Variations of SOD1 have previously been studied
in relation to several clinical manifestations including
amyo-trophic lateral sclerosis (ALS) and diabetes mellitus
(DM) [15-17]. However, to the best of our knowledge,
no studies considering associations between either
gene polymorphism SOD1 35 A/C (rs2234694) or SOD2
A16V (C/T) (rs4880) and vitiligo is currently available in
the literature. The aim of this study was to investigate the
polymorphisms of the SOD1 and SOD2 and their impact
on Turkish vitiligo patients.
|
|
|
|



 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|